Compared to Estimates, SurModics (SRDX) Q1 Earnings: A Look at Key Metrics
The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates
SurModics (SRDX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago.
Here's Why You Should Add Surmodics Stock to Your Portfolio Now
SRDX stock falls more than 6% so far this year. However, this provides a unique opportunity to generate double-digit return within a couple of months.
After Plunging -10.42% in 4 Weeks, Here's Why the Trend Might Reverse for SurModics (SRDX)
SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
SurModics (SRDX) Upgraded to Strong Buy: What Does It Mean for the Stock?
SurModics (SRDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Is SurModics (SRDX) Up 4% Since Last Earnings Report?
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?
SurModics (SRDX) is an Incredible Growth Stock: 3 Reasons Why
SurModics (SRDX) could produce exceptional returns because of its solid growth attributes.
Surmodics Q4 Earnings and Revenues Beat Estimates, Margin Down
SRDX fiscal fourth-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.
SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates
SurModics (SRDX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to earnings of $0.53 per share a year ago.
SRDX Stock Down Despite FDA Clearance for Pounce XL System
Surmodics' latest regulatory achievement is likely to broaden the platform's clinical utility and significantly expand its addressable market.
SurModics (SRDX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
SurModics (SRDX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Down -5.46% in 4 Weeks, Here's Why SurModics (SRDX) Looks Ripe for a Turnaround
SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
